- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 350 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 132 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech | ||
| 29.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.11.24 | Inhibikase Therapeutics files for secondary offering of common stock | 3 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 | 2 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 194 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| 14.11.24 | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.24 | Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More | 45 | Insider Monkey | ||
| 22.10.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 170,22 | -0,32 % | AbbVie Aktie: Potenzial voll ausgeschöpft! | Der Pharmakonzern veröffentlicht seine Finanzdaten für Q1/2025 am 25. April und baut durch strategische Investitionen seine Position im wachsenden ADC-Markt aus. AbbVie wird seine Finanzergebnisse für... ► Artikel lesen | |
| TEVA | 12,500 | -1,19 % | Medincell's Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI | Regulatory News:
Medincell (Paris:MEDCL):
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 4,406 | +5,03 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| BAUSCH HEALTH | 4,807 | -1,22 % | Bausch Health Companies Inc.: Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month | Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,875 | -7,33 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.04.2025 | Das Instrument 0OG0 CA68620P7056 ORGANIGRAM HLDGS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 01.04.2025 und ex Kapitalmassnahme am 02.04.2025 The instrument 0OG0 CA68620P7056 ORGANIGRAM HLDGS... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 6,600 | +1,54 % | Geschäftsbericht 2024 von Quantum Biopharma zeigt starke Verbesserungen bei Barmitteln, Betriebskapital und Betriebseffizienz sowie Beseitigung von wesentlichen Unsicherheiten hinsichtlich laufendem Geschäft | Abschluss von klinischer Studie über unbuzzdTM und Phase-1-Studie über
Multiple-Sklerose-Medikament Lucid-21-302 erweitern die Produkt- und Assets-Pipeline des Unternehmens
Toronto... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,560 | +7,04 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 100,55 | 0,00 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference | DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,959 | +0,42 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update | - Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,826 | +1,98 % | XORTX Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| BRIDGEBIO PHARMA | 28,240 | -1,47 % | BridgeBio Pharma, Inc.: Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM | Acoramidis's hazard ratio of.41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 284,00 | -1,18 % | AKTIONÄR-Hot-Stock Madrigal: Erneute Übernahmegerüchte - Aktie mit Kurssprung | Am späten Freitagabend hat die Aktie des Biotech-Unternehmens Madrigal einen starken Kursanstieg verzeichnet. Erneut halten sich Gerüchte um die Gesellschaft, die mit Rezdiffra (Resmetirom) die erste... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 48,400 | -1,63 % | Verona Pharma plc: Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS | RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,080 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,801 | -7,61 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2024 | Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,135 (-6,84 %) liegt der Kurs bei 1,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
